A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

Limited therapeutic options exist for the treatment of patients with triple negative breast cancer (TNBC). Neoadjuvant chemotherapy is currently the standard of care treatment in the early stages of the disease, although reliable biomarkers of response have been scarcely described. In our study we e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Pérez-Pena, Javier, Tibor Fekete, Janos, Páez, Raquel, Baliu-Piqué, Mariona, García-Saenz, José Ángel, García-Barberán, Vanesa, Manzano, Aránzazu, Pérez-Segura, Pedro, Esparis-Ogando, Azucena, Pandiella, Atanasio, Gyorffy, Balázs, Ocana, Alberto
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2019
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930158/
https://ncbi.nlm.nih.gov/pubmed/31921107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.02802
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars